Overexpression of receptor tyrosine kinases (RTKs) has been implicated in cancer. Increasing evidence suggests that dysregulation of RTKs is reported in many neurodegenerative and psychiatric disorders.
Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders provides a fundamental, pragmatic map of RTKs structure, activation, functions, mechanism of action, gene regulation, and signaling pathways in developing central nervous system (CNS), adult normal CNS, neurodegenerative and psychiatric disorders. Additionally, the structure, function, activation, and therapeutic potential of many growth factors have been covered. Here, international experts in the field offer a comprehensive discussion of results of pre-clinical and clinical studies of repositioning of anti-cancer receptor tyrosine kinase inhibitors (RTKIs) and other promising protein kinase inhibitors in various neurodegenerative disorders including, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington's disease, and multiple sclerosis, and psychiatric disorders including, anxiety, depression, alcohol use disorder, and schizophrenia. In addition, the book discusses the obstacles and opportunities for the potential repositioning of kinase inhibitors in neurodegenerative and psychiatric disorders.

• Provides a thorough overview of RTKs biology and their role in health and disease progression and modulation
• Highlights RTK families and the numerous receptors within each subfamily
• Examines RTKIs and other protein kinase inhibitors in pre-clinical and clinical trials in both neurodegenerative and psychiatric disorders
• Gives future directions of possible safe effective targeted RTKIs and other protein kinase inhibitors that may be repositioned in various neurodegenerative and psychiatric disorders
• Includes chapter contributions from renowned experts in biology, pharmacology, neurology, psychiatry, and oncology